Microbiome Therapeutics prepares to launch first microbiome modulator after completing Series B financing

261828b1-e8b6-4c71-a5dc-0270aa80590barticleimage.jpg

08 Nov 2017 --- MicroBiome Therapeutics, LLC (MBT), a company that applies the science of the gastrointestinal (GI) microbiome to promote health and wellness, has announced the completion of a Series B financing that raised approximately US$1 million. MBT intends to use the proceeds to launch its clinically-tested microbiome modulator product in 2018.

The dietary supplement is specifically designed to balance and optimize the GI tract and promote healthy metabolism by nourishing and nurturing the growth of healthful gut bacteria, MBT notes. New and existing investors include Lagniappe Angels, NO/LA Angel Network, Zehnder Communications and other private investors.

“We appreciate the support of our investors, which will enable the planned launch of our lead microbiome modulator next year,” says Dale Pfost, Acting CEO of MBT. “This product is a scientific formulation of natural ingredients designed to support a balanced GI microbiome and promote metabolic health in an easy-to-use, flavorful drink mix.”

“Our two clinical trials, conducted at the Pennington Biomedical Research Center and reported in peer-reviewed publications, demonstrated its benefits in helping to manage hunger, maintain healthy blood sugar levels and promote regularity,” Pfost adds.

The product is described as an all-natural blend of prebiotics, including fermentable fiber and polyphenol antioxidants in a patent-pending blend intended to help nurture and nourish beneficial microorganisms in the lower gut.

MBT reports that the launch of its microbiome modulator will be supported by a two-year e-commerce and social media campaign conducted in partnership with New Orleans-based advertising agency Zehnder Communications. MBT is also assembling a nationwide network of registered dietitians and certified diabetic educators to support the launch.

“With MicroBiome Therapeutics, we saw a unique opportunity to apply our product launch expertise in support of an exciting, first-in-class product from a leading science-based company,” says Jeremy Hunnewell, CFO and Business Strategist for Zehnder Communications. “We believe our expertise, along with our integrative and analytical approaches, will enable MBT to inform and educate consumers about this exciting new type of health-promoting dietary supplement.”

“Our investment reinforces our commitment to making a difference by playing a part in the microbiome revolution,” states Hunnewell, who will be joining the board of directors of MBT.

To contact our editorial team please email us at editorial@cnsmedia.com

RELATED ARTICLES
Homepicture

Clean label: Laboratoire PYC goes for transparency in supplements

10 Oct 2018 To meet the growing consumer demand for ...

Homepicture

Astaxanthin could help stave off sarcopenia in seniors

10 Oct 2018 A formulation containing AstaReal natural ...

Homepicture

Enhanced beverage portfolio: Keurig Dr Pepper to acquire Core in US$525m deal

28 Sep 2018 Keurig Dr Pepper (KDP) has entered into a ...

Homepicture

Polyol ambitions: Sunar Misir invests in sorbitol and maltitol capacity

24 Sep 2018 Sunar Misir plans to reach an installed capacity ...

Homepicture

Pesticide Testing: NSF International updates dietary supplement certification standard

14 Aug 2018 NSF International and the NSF/ANSI 173 Joint ...